MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced multiple oral and poster presentations at three leading wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2026, taking place April 8–12 in Charlotte, North Carolina, and the European Wound Management Association (EWMA) 2026, taking place May 6–8 in Bremen, Germany.
The presentations will showcase new preclinical and clinical data supporting EscharEx's differentiated mechanism of action, clinical performance, and advancement of its ongoing Phase III development in venous leg ulcers (VLUs), as well as its planned expansion into diabetic foot ulcers (DFUs) and pressure ulcers.
Key Presentation Highlights
Wound Healing Society (WHS)
- A new preclinical mechanistic study demonstrated superior debridement with EscharEx versus SANTYL across multiple non-viable tissue components, while gene expression analysis revealed that EscharEx specifically activates molecular pathways that support wound healing.
Symposium on Advanced Wound Care (SAWC)
- New analysis demonstrating improved long-term scar outcomes following enzymatic debridement compared to surgical and non-surgical standard of care.
- New data on time to wound closure following autograft or placental-derived allografts in VLUs, supporting the statistical assumptions of the ongoing VALUE Phase III study.
- Post-hoc analysis from the ChronEx Phase II multicenter randomized controlled trial highlighting that adequate wound bed preparation is a prerequisite for wound closure, supporting the co-primary endpoint of the VALUE Phase III study.
- Scientific session highlighting the expanding role of bromelain-based enzymatic therapy from acute burn care to chronic wound management, including clinical case studies, comparison to SANTYL, Phase III VALUE trial updates in VLUs, and future development in DFUs and pressure injuries.
European Wound Management Association (EWMA)
- Post-hoc analysis demonstrates the efficacy of bromelain-based enzymatic debridement in DFUs, supporting ongoing development in this indication.
- Additional analyses from the ChronEx Phase II randomized controlled trial, further strengthening the clinical foundation for the ongoing VALUE Phase III study.
"These new data further support EscharEx's unique mechanism of action, which extends beyond debridement to support key wound healing processes," said Dr. Ety Klinger, PhD, Chief Medical Officer at MediWound. "Importantly, EscharEx is based on the same bromelain-derived active ingredient as NexoBrid, our FDA-approved biologic, providing established clinical validation of this mechanism. The breadth of data reinforces our ongoing VALUE Phase III study in venous leg ulcers and supports our planned expansion into diabetic foot and pressure ulcers."